MELAS syndrome is a mitochondrial disorder that is caused mainly by the m.3243AN G mutation in mitochondrial DNA. Here, we report on how the severity of pathophysiological alterations is differently expressed in fibroblasts derived from patients with MELAS disease. We evaluated mitophagy activation and mitochondrial biogenesis which are the main mechanisms regulating the degradation and genesis of mitochondrial mass in MELAS fibroblasts and transmitochondrial cybrids. Our results suggest a critical balance between mitophagy and mitochondrial biogenesis which leads to the expression of different degrees of pathological severity among MELAS fibroblast cell lines according to their heteroplasmy load and the activation of AMP-activated protein kinase (AMPK). AMPK-activators such as 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) or coenzyme Q 10 (CoQ) increased peroxisome proliferator-activated receptor alpha (PGC-1α) nuclear translocation, mitochondrial biogenesis, antioxidant enzyme system response, autophagic flux and improved pathophysiological alterations in MELAS fibroblasts with the most severe phenotype. Our findings support the hypothesis that mitochondrial biogenesis, increased antioxidant response and autophagy clearance serve as compensatory mechanisms in response to mitophagic degradation of dysfunctional mitochondria and point out that AMPK is an important player in this balance.
Introduction
MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) syndrome is a genetically and clinically heterogeneous mitochondrial disorder which is associated with neurologic symptoms such as seizures, encephalopathy and stroke-like episodes and other secondary manifestations such as short stature, cognitive dysfunction, migraine, depression, cardiomyopathy and diabetes mellitus [1] [2] [3] [4] . Although there are at least 29 specific mutations reported, 80% of MELAS patients harbour a transition of adenine to guanine in the 3243 position in the tRNA Leu (UUR) gene of mtDNA (MT-TL1 gene). The mutation affects the modifications of the wobble U base that impairs translation at UUA and UUG codons, deriving in defective incorporation of amino acids in mitochondrial proteins encoded by mtDNA [5] . Particularly, proteins rich in codons UUG, like ND6 subunit of complex I, are mainly affected [6, 7] . Thus, MELAS disease is often associated with a general defect in mitochondrial protein synthesis and severe mitochondrial respiratory chain defects [8, 9] . The A3243G mutation induces high rate of glycolysis followed by lactic acid accumulation, diminished pyruvate oxidation by mitochondria, reduced mitochondrial membrane potential (ΔΨm), decreased ATP production, altered cellular calcium homeostasis, high production of reactive oxygen species, Diabetes Mellitus (by impaired insulin secretion), early aging, and dysregulation of genes involved in the biosynthesis of amino groups and urea [10] [11] [12] .
Recently, both autophagy and mitophagy have been implicated in the pathophysiology of mitochondrial diseases [13, 14] . Autophagy is an evolutionarily conserved process that is responsible for the bulk degradation of cytoplasmic components, including entire organelles as mitochondria, via the lysosomal pathway [15] . On the other hand, the term mitophagy describes the selective sequestration and subsequent degradation of dysfunctional mitochondria [16] . Mitophagy and mitochondrial biogenesis are the main mechanisms regulating the degradation and genesis of mitochondrial mass.
In previous works we have demonstrated that mitophagy and impaired autophagic flux play a central role in the pathophysiological alterations found in fibroblasts derived from MELAS patients [13, 17] . Induction of mitophagy results in the specific elimination of dysfunctional mitochondria in MELAS fibroblasts. Thus, damaged mitochondria are selectively degraded by mitophagy, ensuring the maintenance of a functional mitochondria population. Mitophagy depends on the general autophagic components and is activated in response to general signals, including nutrient deprivation and oxidative stress, or specific signals like mitochondrial damage. In mammals, new autophagic processrelated proteins like NIX, participate like a receptor interacting with LC3 and GABARAP [18] , or Parkin which seems to point up to the autophagic selectivity translocating to depolarized mitochondria [19] . This selective tagging of depolarized mitochondria induces the formation of a double membrane which circled the damaged mitochondria and generates the autophagosome [16, 20] . Atg12-Atg5 is an essential protein complex required to elongation of the autophagosome [21] [22] [23] as well as LC3, acting as a microtubular-autophagosome adaptor, is a necessary protein for the movement of autophagosomes along microtubules to the lysosomes in the perinuclear zone of the cells to generate the autolysosome [24] . The autophagic adaptor p62/SQSTM1 links with LC3 and ubiquitin residues of tagged proteins by Parkin [25, 26] .
On the other hand, mitochondrial biogenesis is a complex process mediated by the coordinated transcription and translation of nuclear and mitochondrial genes, the protein transport from cytosol to mitochondria and the mitochondrial turnover [27] . Mitochondrial biogenesis in turn includes two processes, the proliferation and the differentiation whereby mitochondria get their structural and functional characteristics [28] . Peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1α) is a metabolic regulator that coactivates the transcriptional activity of nuclear respiratory factors NRF1 and NFR2 and induces mitochondrial transcriptional factor A (mtTFA) expression [29] . This cascade finishes with mtDNA replication and mitochondrial fission [30, 31] . One of the key proteins of the PGC-1α activation is 5′AMP-activated protein kinase (AMPK) which binds directly PGC-1α and phosphorylates it [32] .
MELAS syndrome has no cure but there are palliative treatments of the symptoms at the cardiac, renal, growth and nutritional level. The most common pharmacological treatment is usually based in cocktails of different drugs combining several strategies that can improve patient health [33] . Recently, our group has shown that the treatment with riboflavin or coenzyme Q 10 (CoQ) improved the pathophysiological alterations in MELAS cell models [17] .
Furthermore, recent evidences on the role of mitochondrial biogenesis in mitochondrial diseases are bringing to light new target proteins like AMPK and thus, it has been reported that drugs such as metformin or 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) are the most beneficial compounds in Complex I deficient patient's fibroblasts [34] . Moreover, there are evidences that many beneficial effects of CoQ supplementation are mediated by AMPK activation [35] [36] [37] .
In this work, we examined the balance between mitophagy and mitochondrial biogenesis in four MELAS fibroblast cell lines and MELAS cybrids, and the efficiency of AMPK activators, such as AICAR and CoQ, in the improvement of the pathophysiological alterations associated with the disease.
Material and methods

Reagents
We purchased the following antibodies and chemicals: Monoclonal Anti-Actin antibody, Anti-α-tubulin, compound C, CoQ, AICAR and trypsin-EDTA solution from Sigma-Aldrich ( 
Fibroblast cultures
Samples from patients and controls were obtained according to the Helsinki Declarations of 1964, as revised in 2001. Cultured fibroblasts were derived from skin biopsies of four patients (MELAS 1, MELAS 2, MELAS A and MELAS B) carrying a heteroplasmic m.3243ANG mutation. The heteroplasmy load analysis showed that MELAS 1 and MELAS 2 harboured higher mutation load than MELAS A and MELAS B fibroblasts (MELAS 1: 17%, MELAS 2: 26%, MELAS A: 9% and MELAS B: 4%). We verified that heteroplasmy load did not shift significantly during this work. Age-/sex-matched control fibroblasts, at similar low passage number were derived from two healthy volunteers. When indicated in the figure legends, control data were shown as a mean of two control fibroblast cultures. Fibroblasts from the MELAS patient and controls were cultured at 37°C in DMEM containing 4.5 g/L glucose, L-glutamine, and pyruvate supplemented with an antibiotic/antimycotic solution and 20% fetal bovine serum.
Construction of transmitochondrial cybrid cell lines
143B osteosarcoma cybrid clones were generated as previously described [17] . Control osteosarcoma cybrid cells (100% wild-type) and cybrid cells carrying the m.3243AN G mutation (90% heteroplasmy) were cultured in DMEM containing 4.5 g/L glucose, supplemented with 5% FBS, sodium pyruvate (100 μg/ml), uridine (50 μg/ml), penicillin (100 IU/ml) and streptomycin (100 μg/ml). Heteroplasmy load in MELAS cybrids did not shift significantly during the study. To induce respiration and make more evident the mitochondrial defects, cybrids clones were cultured in a glucose-restricted medium using DMEM 2.5 g/L glucose, L-glutamine (GIBCO Life technologies, UK) supplemented with 1% antibiotic/antimycotic solution (PAA Laboratories GmbH, Austria) and uridine 50 μg/ml (Sigma-Aldrich) and 2% fetal bovine serum (PAA Laboratories GmbH, Austria).
Measurement of mutant heteroplasmy
Heteroplasmy was determined by PCR-RFLP. DNA amplification was performed by using reverse primer 5′-AGTAATGTTGATAGTAGAAT-3′ and forward primer 5′-ATTTATTAATGCAAACAGTA-3′. PCR conditions for all reactions were 94°C for 5 min, 35 cycles with denaturation at 94°C for 35 s, annealing at 55°C for 35 s and elongation at 72°C for 1 min; 1 cycle at 72°C for 7 min, and a final hold at 4°C. After PCR, the amplicon was digested with Apa I (Fermentas, Burlington, Ontario, Canada) for 5 h 37°C and DNA fragments were separated in 1% agarose gel. Gels stained with RedSafe Nucleic Acid Staining Solution (iNtRON Biotechnology, Inc., Korea) were placed on a UV light transilluminator and PCR and digested products were visualized. The bands were analyzed using ImageJ software.
Cells treatment
Fibroblasts and transmitochondrial cybrids were treated with 100 μM CoQ, 100 μM AICAR. Fibroblasts were exposed to these drugs during 1 week whereas the cybrid cells were incubated during 48 h. The pharmacological inhibition of AMPK was achieved with 10 μM compound C supplementation 12 h before harvesting the cells. The pharmacological inhibition of autophagy flux was achieved with 100 nM Bafilomycin A1 supplementation 12 h before harvesting the cells.
Mitochondrial respiratory chain enzyme activities
Activities of NADH:coenzyme Q1 oxidoreductase (complex I), succinate dehydrogenase (complex II), cytochrome c oxidase (complex IV), ubiquinol:cytochrome c oxidoreductase (complex III), NADH: cytochrome c reductase (complex I + III), succinate:cytochrome c reductase (complex II + III) were determined in cell extracts using spectrophotometric methods previously described [38, 39] . Results are expressed as units of activity (U)/citrate synthase activity (CS) (mean ± standard deviation). Proteins of fibroblasts homogenates were determined by the Bradford procedure [40] . Complex II (succinate dehydrogenase, SDH) activity was also visualized cytochemically in cell cultures grown on coverglass as described [41] .
CoQ determination
Cell samples were lysed with 1% SDS and a mixture of ethanol:isopropanol (95:5). In order to recover CoQ we used hexane and several centrifugations at 1000 × g for 5 min at 4°C. The upper phases from three extractions were recovered and dried using a rotary evaporator. Lipid extracts were suspended in ethanol, dried in a speedvac and stored at − 20°C up to the HPLC analysis (Shimadzu, Kyoto, Japan). CoQ levels were determined with an ultraviolet detector. Coenzyme Q 9 (CoQ 9 ) was used as an internal standard. CoQ content was expressed as pmol/mg protein [42] .
Measurement of intracellular generation of reactive oxygen species (ROS)
Flow-cytometric analysis of the intracellular generation of ROS was performed using MitoSOX TM Red (Invitrogen/Molecular Probes, Eugene, OR, USA), a fluorochrome specific for anion superoxide generated in mitochondria. Cells were cultured in 6-well plates (35 mm diameter well) and, at confluence, incubated with MitoSOX TM Red (5 μM) for 30 min at 37°C. After incubation cells were harvested and analyzed by flow cytometry (FACScalibur TM , BD Biosciences, San Jose, CA, USA).
Mitochondrial mass
Mitochondrial mass was determined by flow cytometry after staining the cells with 10 μM Nonyl-Acridine orange (NAO) for 10 min at 37°C in the dark. NAO specifically binds to cardiolipin and it is used to estimate mitochondrial mass. However, it has been reported that NAO fluorescence is dependent upon mitochondrial membrane potential [43] . To determine whether NAO binding was dependent on mitochondrial potential, NAO fluorescence was determined in the absence and presence of the uncoupler FCCP (1 μM). Mitochondrial mass was also estimated by measuring citrate synthase activity. Cellular homogenates were incubated for 2 min with a solution 75 mM Tris-HCl pH 8, 1 mM 5,5-dithiobis(2-nitrobenzoate) (DTNB), 0.1% Triton X-100 and 350 mg/ml acetyl CoA. After incubation 500 μM oxaloacetate was added. The increase in absorbance was used to calculate citrate synthase activity [38, 44] . The fluorescence signals of JC-1 monomers and aggregates were detected through the FL1 (525 ± 5 nm band pass filter) and FL2 channels (575 ± 5 nm band pass filter), respectively. To confirm the results of the TMRE and JC-1 analysis, cells were stained with 100 nM MitoTracker Red CMXRos (Molecular Probes; Invitrogen) for 30 min at 37°C, washed, and fixed with 4% paraformaldehyde for 10 min at room temperature. After washing, cells were visualized using a DeltaVision system (Applied Precision; Issaquah, WA, USA) with an Olympus IX-71 microscope.
Mitochondrial morphology assessment
Mitochondrial size and shape were quantified by ImageJ (NIH) software. Mitochondria that were longer than 0.5 μm were defined as tubular mitochondria. To assure accuracy in the scoring process, mitochondrial size and shape were determined and analyzed independently by two investigators. More than 200 clearly identifiable mitochondria from 50 cells per experiment, randomly selected, were measured in three independent experiments.
Lysosomal content assay
Cells were cultured in 6-well 35 mm plates, until confluence. Next, cells were incubated for 30 min with 75 nM LysoTracker™ Red (Invitrogen/Molecular Probes) a fluorophore which is concentrated in cell acidic vacuoles. After incubation, cells were washed, and the red fluorescence of LysoTracker™ was measured by flow cytometry.
ATP/ADP quantification assay
ATP and ADP levels were assayed by using a luciferase-based assay, according to the instructions of the manufacturer (ADP/ATP Ratio Assay Kit, Sigma-Aldrich), using a Tuner Designs Luminometer TD 20/20 (Sunnyvale, CA, USA).
Immunoblotting assay
Western blotting was performed using standard methods. After protein transfer, the membrane was incubated with various primary antibodies at a 1:1000 dilution, and then with the corresponding secondary antibody coupled to horseradish peroxidase at a 1:2500 dilution. Specific protein complexes were identified using the Immun Star HRP substrate kit (Biorad Laboratories Inc., Hercules, CA, USA).
Cell fractionation and isolation of nuclear proteins
After treatments, cells were pelleted and washed using buffer A (10 mM Hepes-KOH pH 7.9, 15 mM MgCl 2 , 10 mM KCl). Then, cells were centrifuged 5 min at 13,000 rpm 4°C. While supernatant was discarded (cytoplasmic proteins), the pellet was resuspended in buffer B (20 mM Hepes-KOH pH 7.9, 1.5 mM MgCl 2 , 25% Glycerol, 0.2 mM EDTA, 420 mM NaCl) and incubated 20 min on ice. Buffers A and B were supplemented with 1 mM DTT, 0.5 mM PMSF, 1 mM NaF and 1 mM sodium orthovanadate. Finally, we centrifuged the solution for 2 min at 13,000 rpm and nuclear proteins (supernatant) were collected. Nuclear proteins were frozen in liquid nitrogen and stored as aliquots at −80°C until further analysis.
Immunofluorescence microscopy
Fibroblasts were grown on 1 mm glass coverslips (Thermo Scientific™ Gold Seal™, Waltham, MA, USA). Cells were rinsed once with PBS, fixed in 3.8% paraformaldehyde for 10 min at room temperature, and permeabilized with 0.1% saponin for 10 min. For immunostaining, glass coverslips were incubated with primary antibodies diluted 1:100 in PBS. Secondary antibodies were diluted 1:100 in PBS and added on the coverslip. The samples were incubated for 1 h at 37°C. Coverslips were then rinsed with PBS, incubated for 10 min with Hoechst 33342 (1 mg·ml −1 ) and washed with PBS (3 times 5 min).
Finally, the coverslips were mounted onto microscope slides using Vectashield Mounting Medium (Vector Laboratories, Burlin-game, CA, USA) and analyzed using an upright fluorescence microscope (Leica DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Deconvolution studies and 3D projections were performed using a DeltaVision system (Applied Precision; Issaquah, WA, USA) with an Olympus IX-71 microscope.
Mitophagy analysis
Mitophagy analysis was performed by LC3B and cytochrome c immunostaining. Colocalization analysis was assessed using the DeltaVision software and calculating the Pearson's coefficient of correlation. Rounded and fragmented mitochondria resulted usually in mitophagic events. Positive punctata (LC3B/cytochrome c positive) were considered when Pearson´s coefficient of correlations were higher than 0.75. Mitophagic cells were scored when more of 10 punctata were observed in the cells. Data were represented as mitophagic cells with respect to total measured cells. Results are expressed as mean ± SD.
Proliferation assay
Cells were seeded (N 0 ) in 6-well plates. After a week of incubation cells were harvested and cells were quantified (N) by using a conventional Neubauer counter chamber. Cell viability was assessed by trypan blue exclusion. Proliferation rate (n) was calculated by using the formula N = N 0 × 2 n . Results are expressed as mean ± SD.
Electron microscopy
Electron microscopy was performed using a protocol previously described by our group [42] . For quantification of autophagic vesicles per 10 μm 2 of cytoplasma, the number of autophagosomes and autophagolysosomes were scored in 50 cells. Data are presented as mean ± SD.
Statistical analysis
All results are expressed as mean ± SD, unless stated otherwise. The measurements were statistically analyzed using Student's t-test for comparing two groups and ANOVA for more than two groups. P-values of less than 0.05 were considered significant.
Results
Mitophagy activation in MELAS fibroblasts
Pathophysiological alterations were characterized in primary culture fibroblasts derived from four different MELAS patients (MELAS 1, MELAS 2, MELAS A, MELAS B) carrying the m.3243A N G mutation with different mutation load (MELAS 1: 17%, MELAS 2: 26%, MELAS A: 9% and MELAS B: 4%) and control fibroblasts derived from healthy volunteers.
As mitochondrial dysfunction and degradation of impaired mitochondria have been reported in MELAS fibroblasts [13, 14] , we first assessed if mitophagic activation was a general phenomenon in the four MELAS fibroblasts cell lines. As lysosomal content is usually increased when autophagy is activated, we quantified the amount of acidic vesicles using Lysotracker Red ® staining and flow cytometry analysis. Lysosomal content was significantly increased in the four MELAS fibroblasts cell lines with respect to control fibroblasts (Fig. 1A) . Given that mitophagy needs the autophagy machinery we next determined the protein expression levels of well-known autophagic markers and mediators such as ATG12-ATG5 conjugated and LC3B-II. As shown in Fig. 1 and C, ATG12-ATG5 conjugated and LC3B-II protein expression levels were higher in MELAS fibroblasts than in control cells suggesting autophagy activation. Then, we assessed if mitochondria were selectively degraded by mitophagy in MELAS fibroblasts. Mitophagy was detected by labelling a mitochondrial protein as cytochrome c and an autophagosome associated protein as LC3B. In this experiment, we used cytochrome c as a mitochondrial marker to assess the specificity of MitoTracker staining and to verify that mitochondrial depolarization in MELAS fibroblasts was not a result of cytochrome c release, as occurs in apoptosis. Colocalization of LC3B/cytochrome c proteins was found in the four MELAS cell lines indicating the activation of the selective degradation of mitochondria (Fig. 1E , D and F). Colocalization studies also revealed that high LC3B/cytochrome c colocalization was detected in the small rounded fragmented mitochondria population (white arrows) while it was not observed in the normal tubular mitochondrial network (red arrows) (Fig. 1F ). Mitophagy activation in MELAS fibroblasts was also confirmed by electron microscopy ( Supplementary Fig. 1 ).
To check for autophagosome maturation and autophagic flux in MELAS fibroblasts, we used bafilomycin A1, a specific inhibitor of vacuolar H + -ATPases and a blocker of autophagosome-lysosome fusion.
Control and MELAS fibroblasts were incubated for 12 h in the presence of bafilomycin A1. As expected, bafilomycin A1 treatment in control fibroblast cells led to a significant increase in the LC3B II/LC3 B I ratio, suggesting that autophagic flux is normal in control cells (Supplementary Fig. 2 ). However, bafilomycin A1 treatment in MELAS 1 fibroblasts had no effect on LC3B II/LC3 B I ratio, indicating that autophagic flux was severely impaired in MELAS 1 fibroblasts with high heteroplasmy load ( Supplementary Fig. 2 ). In contrast, bafilomycin A1 treatment in MELAS B fibroblasts had a slight effect on LC3B II/LC3B I ratio, indicating that autophagic flux was moderately impaired in MELAS B fibroblasts with low heteroplasmy load ( Supplementary Fig. 2 ). The colocalization of mitochondrial and autophagosomal markers analysis also showed that MELAS 1 and MELAS 2 fibroblasts frequently showed massive mitochondrial degradation and a poor tubular mitochondrial network, while MELAS A and MELAS B fibroblasts showed mitophagy activation but also a rich mitochondrial tubular network ( Fig. 1E and F) . These results may suggest that mitochondrial biogenesis activation was compensating mitochondrial degradation in MELAS A and MELAS B fibroblasts but not in MELAS 1 and MELAS 2 fibroblasts.
Mitochondrial membrane potential (ΔΨm) is usually a good marker of proper mitochondrial function while mitochondria depolarization is a well-known signal of mitochondrial dysfunction that promotes mitophagy activation [45, 46] . Therefore, we analyzed ΔΨ m by flow cytometry using TMRE. We found that ΔΨ m was reduced by 50-60% in the four MELAS fibroblasts cell lines with respect to control fibroblasts (Fig. 2A) . Mitochondrial depolarization in MELAS fibroblasts was also verified by using the ratiometric probe JC-1 ( Supplementary Fig. 3 ).
To confirm that the changes in ΔΨm were the result of mitochondrial polarization and not caused by alterations in mitochondrial mass or proliferation, individual mitochondria were examined in control and MELAS fibroblasts by fluorescence microscopy. MitoTracker and cytochrome c staining and examination of individual mitochondria confirmed the presence of depolarized mitochondria in the four MELAS fibroblasts cell lines with respect to control fibroblasts (Fig. 2B) . While control fibroblasts show a normal polarized mitochondrial tubular network (Fig. 2C) , two populations of mitochondria with different polarization levels were observed in the four MELAS cell lines. Fig. 2D and E show that MELAS 1 and MELAS A fibroblasts content mitochondria with different polarization levels as indicated with white (low polarization) and cyan arrows (high polarization). Representative high size images of MELAS 2 fibroblasts stained with MitoTracker and quantification of mitochondrial network are showed in Supplementary Fig. 4 .
Mitophagy in MELAS fibroblasts was associated with Parkin translocation to depolarized mitochondria, which is a well established mechanism for the selective elimination of mitochondria in mammalian cells ( Supplementary Fig. 5 ).
Differential pathophysiology in MELAS fibroblasts
To further examine the pathophysiological alterations in MELAS fibroblasts, we analyzed proliferation rate, ATP and ADP levels, respiratory chain enzyme activities, CoQ levels and reactive oxygen species production, as indicators of mitochondrial function. Results revealed a differential pathophysiological severity among the four MELAS fibroblasts cell lines. Proliferation rate assays shows the growth capacity of the different fibroblasts cultures. High growth levels were considered as a signal of proper cellular function. On the contrary, low growth rates were considered as a lack of optimum cellular conditions. Two patterns of growth rates were observed in MELAS fibroblasts. Growth rate was decreased by~54% and 34% in MELAS 1 and MELAS 2 respectively, whereas it was near to control values in MELAS A and MELAS B cultures (Fig. 3A) . As low proliferation rate could be explained as a lack of energy production to support proper cell division, we determined ATP/ADP ratio in control and MELAS fibroblasts. ATP/ADP ratios were notably decreased in MELAS 1 and MELAS 2 while they were not significantly altered in MELAS A and MELAS B fibroblasts (Fig. 3B ). Since energyproduction in MELAS 1 and MELAS 2 cultures was impaired, we next examined if this alteration could be associated with mitochondrial dysfunction. As mitochondrial dysfunction is associated with increased reactive oxygen species (ROS) production in mitochondria, we examined ROS levels in MELAS cultures by flow cytometry using MitoSOX as a mitochondrial superoxide sensor. ROS levels were increased by 5-7 fold in MELAS 1 and MELAS 2 fibroblasts whereas they were close to control values in MELAS A and MELAS B fibroblasts (Fig. 3C) . These results suggest that mitochondria dysfunction severity and the proper activation of the cellular antioxidant system may participate in the differential pathophysiology showed in the four MELAS cell lines.
CoQ is a fundamental component of the mitochondrial respiratory chain (MRC) transporting electrons from complexes I and II to complex III. As CoQ deficiency has been recently detected in mitochondrial diseases caused by mtDNA mutations [47] , we next determined CoQ levels in MELAS fibroblasts. CoQ levels were reduced by 50% with respect to controls in MELAS 1 and MELAS 2 fibroblasts. However, CoQ levels were increased by 1.7-2.7 fold in MELAS A and MELAS B fibroblasts, respectively (Fig. 3D) . These data indicate the presence of a CoQ deficiency in MELAS 1 and MELAS 2 but not in MELAS A and MELAS B fibroblasts.
To further assess the functional consequences of this differential pathophysiology, we analyzed mitochondrial protein expression levels by immunoblotting in control and MELAS fibroblasts. As shown in Fig. 3E and F, MELAS 1 and MELAS 2 showed a significant reduction in mitochondrial protein expression levels. Complex I was reduced bỹ 40%, Complex II by~75%, Complex III by~70% and Complex IV by~7 3%. However, MELAS A and MELAS B showed higher expression levels of mitochondrial complexes proteins which were near to control values.
To further confirm if reduced mitochondrial protein expression levels had an effect on mitochondrial function, we measured respiratory chain enzymes activity in control and MELAS fibroblasts. The activity of all of the mitochondrial respiratory chain complexes were significantly reduced in MELAS 1 and MELAS 2 fibroblasts (Fig. 4) . Complex IV activity, the most altered, was reduced by~73% (Fig. 4D) . Complex I activity was reduced by 62 and 52% with respect to control values in MELAS 1 and MELAS 2 fibroblasts, respectively (Fig. 4A) . Complex II activity was reduced by~50% with respect to control values (Fig. 4B) . Complex I + III activity and complex II + III were reduced by~35% and 60% in MELAS 1 and MELAS 2 respectively (Fig. 4E and F) . Complex III activity was reduced by~75% and 60% in MELAS 1 and in MELAS 2, respectively (Fig. 4C) . These results support previous publications which reported a reduction in mitochondrial respiratory chain enzymatic activities in MELAS cells. The main part of the literature reports a decrease in complex I and IV activities [48] [49] [50] , but there are also publications of alterations of complex II [51] or complex III activities [52] . On the contrary, mitochondrial respiratory chain enzymatic activities were near or even higher than control values in MELAS A and MELAS B fibroblasts.
Both mitochondrial protein expression levels and respiratory chain activities of complex II were partially restored in MELAS 1 and MELAS 2 after bafilomycin A1 treatment, indicating that excessive lysosomal degradation was indeed the cause of mitochondrial protein and function loss (Supplementary Fig. 6 ).
All together, these results suggest, as expected, that MELAS 1 and MELAS 2 fibroblasts harbouring high mutation load express a more severe pathological phenotype than MELAS A and MELAS B fibroblasts with low mutation load.
Mitochondrial biogenesis as a compensatory mechanism in MELAS fibroblasts
When mitophagy was examined (Figs. 1 and 2 ), a rich proliferating tubular mitochondrial network was found in MELAS A and MELAS B fibroblasts but not in MELAS 1 and MELAS 2 fibroblasts. We then hypothesized that mitochondrial biogenesis was properly activated in MELAS A and MELA B fibroblasts in order to compensate mitochondrial degradation, but this compensatory mechanism was less efficient or absent in MELAS 1 and MELAS 2 fibroblasts. To verify this hypothesis, we examined mitochondrial mass in MELAS fibroblasts by determining the amount of cardiolipin in mitochondrial membranes using nonyl acridine orange in the presence of an uncoupling agent (FCCP) and flow cytometry analysis. We found that mitochondrial mass was reduced by~50% in MELAS 1 and MELAS 2 fibroblasts with respect to control fibroblasts. On the contrary, mitochondrial mass was higher in MELAS A and MELAS B with respect to control levels (Fig. 5A) . Mitochondrial mass was also assessed by determining citrate synthase activity, a mitochondrial matrix enzyme whose activity correlates with mitochondrial mass [53] . As shown in Fig. 5B , citrate synthase activity was significantly reduced by~50% in MELAS 1 and~65% in MELAS 2 fibroblasts. On the contrary, citrate synthase activity was near to control values in MELAS A and MELAS B fibroblasts. These results suggest that mitochondrial proliferation was able to compensate mitochondrial elimination in MELAS A and MELAS B but not in MELAS 1 and MELAS 2 fibroblasts.
To confirm these findings, we examined protein expression levels of three key proteins involved in mitochondrial biogenesis: peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), nuclear respiratory factor 1 (NRF-1) and mitochondrial transcriptional factor A (mtTFA) expression levels were significantly decreased in MELAS 1 and MELAS 2 fibroblasts whereas they were notably increased in MELAS A and MELAS B fibroblasts (Fig. 5C and D) . PGC-1α and NRF-1 protein expression levels in MELAS A and MELAS B were even higher than in control fibroblasts. The expression levels of mtTFA in MELAS A and MELA B were increased with respect to MELAS 1 and MELAS 2 but not higher than control levels. These results support the hypothesis that high expression levels of proteins involved in mitochondrial biogenesis are necessary to maintain high mitochondria mass for compensating mitochondria loss by mitophagy in MELAS A and MELAS B fibroblasts. However this compensatory mechanism was not efficiently activated in MELAS 1 and MELAS 2 fibroblasts.
Enzymatic anti-oxidant system and AMP-activated protein kinase (AMPK)
ROS are mainly produced as a result of mitochondrial dysfunction [54] . Specifically, one main contributor to oxidative stress is hydrogen peroxide (H 2 O 2 ), which is derived from superoxide (O 2 − ) generated in mitochondria. The toxic effects of H 2 O 2 and O 2 − are prevented by catalase and superoxide dismutase that convert these compounds into H 2 O and O 2 . While ROS are normally produced in the normal cellular respiration, high levels are cytotoxic. High ROS production and the activation of ROS sensor proteins as AMPK are required for the activation of the defensive anti-ROS system [55] . Therefore, we examined the protein expression levels of different proteins involved in ROS-scavenging. Catalase and mitochondrial manganese superoxide dismutase (Mn-SOD) expression levels were increased in MELAS A and MELAS B fibroblasts with respect to control fibroblasts (Fig. 5E and F) . On the contrary, the expression levels of both enzymes were dramatically decreased in MELAS 1 and MELAS 2 with respect to control fibroblasts. These results suggest that proper activation of the enzymatic antioxidant system response is achieved in MELAS A and MELAS B but not in MELAS 1 and MELAS 2 fibroblasts.
Finally, given that AMPK activation is a well-known inducer of catalase and Mn-SOD expression levels we also examined the phospho-AMPK/ total-AMPK ratio in MELAS fibroblasts. Phospho-AMPK/total-AMPK ratio was increased in MELAS A and MELAS B but not in MELAS 1 and MELAS 2. In fact a decrease by~35-40% in MELAS 1 and MELAS 2 was found with respect to MELAS A and MELAS B fibroblasts (Fig. 5E and F) .
Pharmacological stimulation of MELAS fibroblasts with AICAR and CoQ
As pathophysiological studies revealed that MELAS 1 and MELAS 2 fibroblasts with high heteroplasmy load showed severe mitochondrial dysfunction associated with high ROS production, decreased mitochondrial mass, impaired enzymatic antioxidant system response and inappropriate AMPK activation, we then studied the effectiveness of AMPK activation by AICAR and CoQ treatment on MELAS fibroblasts pathophysiological alterations. AICAR, an AMP analogue, activates AMP-activated protein kinase (AMPK). AMPK acts as a metabolic regulator that is activated in situations of low energy availability (low ATP/ADP ratios). AICAR is transported into cells by adenosine transporters and metabolized by adenosine kinase to 5-aminoimidazole-4-carboxamide ribonucleoside (ZMP), which mimics all the effects of AMP on the AMPK system [56] . On the other hand, CoQ or ubiquinone is a lipid-soluble molecule present in cell membranes, mainly in the inner mitochondrial membrane. CoQ transfers electrons from complexes I and II to complex III of the mitochondrial respiratory chain; it also works as a ROS scavenger, and it participates in many metabolic pathways including AMPK activation [57] [58] [59] .
Control and MELAS fibroblast were treated with 100 μM AICAR or 100 μM CoQ and the improvement in pathophysiological alterations was analyzed. Proliferation rate of MELAS 1 and MELAS 2 fibroblasts was notably increase after AICAR or CoQ treatments (Fig. 6A) . Especially, the proliferation rate of MELAS 1 fibroblasts treated with CoQ was the most prominent by a 5-fold increase (Fig. 6A) . Likewise, ROS levels in MELAS 1 and MELAS 2 fibroblasts were significantly decreased by 50% after AICAR or CoQ treatments (Fig. 6B) . AICAR and CoQ treatments were also effective in decreasing autophagolysosome accumulation in the four MELAS cell lines (Fig. 6C) . In addition, AICAR or CoQ treatments were effective in improving mitochondrial mass in MELAS 1 fibroblasts determined by measuring citrate synthase activity and ATP levels in MELAS 1 and MELAS A fibroblasts (Fig. 6D and E) . These results suggest that both AICAR and CoQ treatments improved the pathophysiological alterations in MELAS fibroblasts, especially in those with a more severe phenotype (MELAS 1 and MELAS 2).
To further characterization of the effect of AICAR and CoQ treatment, we analyzed the protein expression levels by Western blotting of several key proteins involved in mitochondrial biogenesis (PGC-1α), enzymatic antioxidant defence (Mn-SOD and catalase), regulators of both pathways (as AMPK) and autophagosome accumulation (LC3B-II) in MELAS 1 fibroblasts with the most severe phenotype.
PGC-1α, Mn-SOD, catalase, and AMPK protein expression levels were decreased in MELAS 1 fibroblasts. The expression levels of Mn-SOD and phospho-AMPK were the most affected proteins with a 96% and 82% reduction, respectively (Fig. 7A, B, C, D and E) . Catalase and PGC-1α protein expression levels were reduced by 45% and 65% respectively ( Fig. 7D and E) . AICAR or CoQ treatments restored PGC-1α and catalase protein expression levels. AMPK protein band analysis also revealed the extra-phosphorylated forms of AMPK when the medium was supplemented with AICAR or CoQ for a week (Fig. 7A) .
AICAR or CoQ treatments were also able to reduce autophagosome accumulation in MELAS 1 fibroblasts as assessed by reducing LC3B II levels (Fig. 7A) . Given that AMPK activation has been described to activate autophagy and autophagic flux, we then assessed if AICAR and CoQ treatments in MELAS fibroblasts were able to reduce autophagolysosome accumulation by increasing autophagic flux. Thus, control and MELAS fibroblasts pre-treated with AICAR or CoQ were incubated with the autophagic flux blocker bafilomycin A1 for 12 h and LC3B II expression levels were examined by Western blotting. Bafilomycin A1 incubation induced a significant increased on LC3-II expression levels in AICAR or CoQ treated control and MELAS fibroblasts (Supplementary Fig. 7 ). These results suggested that autophagic flux was indeed increased by AICAR or CoQ treatments. In fact, both AICAR and CoQ were able to increase the expression levels and activation of the down-stream target ULK1, which is an activator of autophagy and required for proper autophagic flux [60] (Supplementary Fig. 8) . Altogether, these data support the hypothesis that AICAR and CoQ treatment reduce autophagosome accumulation in MELAS cells by increasing autophagy clearance. Fig. 9 . Effect of AMPK inhibition on nuclear PGC-1α localization in MELAS 1 and MELAS A fibroblasts. Control and MELAS 1 and MELAS A fibroblasts were treated with 100 μM AICAR or 100 μM CoQ for one week in the presence or absence of 10 μM compound C, an AMPK inhibitor. (A) Quantification of nuclear Phospho-PGC-1α foci using ImageJ software. More than 100 randomly selected cells were analyzed for each experimental condition. Results are expressed as mean ± SD. (B) Western blotting of phospho-PGC-1α in nuclear fractions. (C) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ software. All results were expressed as mean ± SD of three independent experiments. *P b 0.05; **P b 0.01; ***P b 0.001, significance of MELAS with respect to control fibroblasts. PGC-1α is an essential regulator of mitochondrial biogenesis which is also activated by AMPK. AMPK activation increases the expression of PGC-1α mRNA [61] and also its activation by direct phosphorylation [62] . On the other hand, there are evidences of nuclear PGC-1α translocation when it is phosphorylated by other proteins as Protein kinase A (PKA). It seems that PGC-1α is a protein whose subcellular localization is in the nucleus but is permanently interacting with nuclear transporters like CRM1 in order to be exported to the cytoplasm. Phosphorylation of PGC-1α by PKA prevents nuclear export and increases PGC-1α in the nucleus [63] . Therefore the subcellular localization seems to have great importance for the functional activation of pathways like mitochondrial biogenesis. Consequently, we analyzed the subcellular localization of phospho-PGC-1α by immunostaining and fluorescence microscopy examination in the four MELAS fibroblasts cell lines (Fig. 8A and B) . Phospho-PGC-1α predominantly showed cytoplasmic localization in MELAS 1 and MELAS 2 fibroblasts whereas a major presence of phospho-PGC-1α in nuclei was observed in Control, MELAS A and MELAS B fibroblasts. We also quantified phospho-PGC-1α foci in nuclei before and after a week of AICAR or CoQ treatments. We observed that phospho-PGC-1α foci were significantly increased in control, MELAS 1 and MELAS 2 cultures after AICAR or CoQ treatments ( Fig. 8A and B) .
To assess the role of AMPK in PGC-1α nuclear translocation after AICAR or CoQ treatment, we quantified nuclear phospho-PGC-1α foci in the presence or absence of compound C, a selective inhibitor of AMPK. Phospho-PGC-1α nuclear foci were decreased after AICAR or CoQ treatments in the presence of compound C in MELAS 1 and MELAS A cell lines (Fig. 9A) . These results were confirmed by subcellular fractionation techniques and the evaluation of phospho-PGC-1α expression levels in the nuclear fraction by Western blotting (Fig. 9B  and C) . The purity of the nuclear fraction was validated by Western blot analysis of a "house-keeper" marker protein (Lamin B1) specific for the nuclear compartment ( Supplementary Fig. 9 ). Taken together these data suggest that PGC-1α nuclear translocation is impaired in MELAS 1 and MELAS 2 fibroblasts and CoQ and AICAR treatment increase nuclear phospho-PGC1-α foci through AMPK activation. Once in the nucleus, phospho-PGC-1α is supposed to active mitochondrial biogenesis and thus, compensating the deleterious defects of increased mitophagy.
AICAR and CoQ also restored pathophysiological alterations in MELAS cybrid cells harbouring the m.3243ANG mutation
Transmitochondrial cybrid cell lines are indispensable tools in mitochondrial investigation for providing a controlled nuclear background in which to study the molecular mechanisms by which mutations in mtDNA impair cellular function. Thus, the pathophysiological alterations detected in the cybrids clones are supposed to be a function of the dysfunctional mitochondria, independently of the nuclear context [64] .
To confirm that AICAR and CoQ treatments were also effective in MELAS cybrids harbouring the m3243A N G mutation, we examined growth rate, ATP levels, expression levels of LC3 and PGC-1α in control and MELAS cybrid clones. As shown in Fig. 10A growth rate of MELAS cybrids was decreased with respect to control cybrids by 30% and it was restored by AICAR and CoQ treatment (Fig. 10A) . ATP levels were significantly decreased in MELAS cybrids and they were restored by AICAR or CoQ treatments (Fig. 10B) . The protein expression levels of PGC-1α and LC3B were analyzed using Western blotting techniques (Fig. 10C, D and E) . We found increased values of LC3B and low expression levels of PGC-1α in MELAS cybrids which were restored to control values by AICAR or CoQ supplementation. AICAR or CoQ treatments also increased nuclear phospho-PGC-1α foci to normal values ( Fig. 10F  and G) .
Finally, we analyzed AMPK activation and the subcellular localization of PGC-1α when AMPK was inhibited by compound C. Phospho-AMPK expression levels were increased after AICAR or CoQ treatments and they were partially prevented by compound C (Fig. 11A and B) . AMPK inhibition also prevented the increased nuclear phospho-PGC-1α foci after AICAR or CoQ treatments (Fig. 11C) .
To further investigate the effect of AICAR and CoQ on mitochondrial biogenesis in MELAS cybrids, we analyzed citrate synthase activity as a measure of mitochondrial proliferation. Citrate synthase activity was drastically reduced in MELAS cybrids. AICAR or CoQ treatment restored citrate synthase activity that was partially prevented by AMPK inhibition by compound C (Fig. 11D) . AICAR and CoQ were also able to increase autophagy flux in MELAS cybrids (Supplementary Fig. 10 ).
All together, these results suggest that both AICAR and CoQ effects are mediated, at least partially, by AMPK activation.
Discussion
In this work, we showed the pathophysiological alterations in primary cultured fibroblasts derived from 4 patients with MELAS disease carrying the m.3243A NG mutation with different heteroplasmy load. We found that MELAS fibroblasts can be differenced according to their pathophysiological alterations severity: a first group with severe pathophysiological alterations (MELAS 1 and MELAS 2), and a second group with slight pathophysiological alterations (MELAS A and MELAS B). MELAS fibroblasts with high mutational load (MELAS 1 and MELAS 2) showed low growth rates, reduced ATP/ADP ratio and CoQ levels, high ROS production and low enzymatic antioxidant system, dysfunctional mitochondrial respiratory chain activities, mitophagy activation, impaired autophagic flux and poor tubular mitochondrial network associated with low AMPK activation and PGC-1α, TFAM, and NRF1 down-regulation.
On the contrary, MELAS fibroblasts with low mutational load (MELAS A and MELAS B) also showed mitophagy activation but without alterations of most of the pathophysiological parameters. MELAS A and MELAS B showed a rich tubular mitochondrial network associated with high AMPK activation and PGC-1α, TFAM, and NRF1 up-regulation and manifest a similar phenotype to control fibroblasts.
Furthermore, AICAR or CoQ supplementation reverts many of the pathological alterations found in MELAS 1 and MELAS 2 fibroblasts with the more severe phenotype. The beneficial effect of both AICAR and CoQ seems to be mediated trough AMPK activation because it was partially inhibited by compound C, an AMPK inhibitor. AICAR and CoQ treatment induced AMPK activation and increased nuclear PGC-1α translocation associated with increased mitochondrial biogenesis. All together, these results suggest that AMPK activation by AICAR or CoQ, in a context of low AMPK activity, is capable of compensating most of the pathophysiological alterations in MELAS fibroblasts. On the contrary, inappropriate AMPK activation leads to impaired autophagic flux, autophagolysosome accumulation, inadequate antioxidant defence, deficient compensatory mitochondrial biogenesis and the expression of a more severe phenotype.
Our results suggest a critical balance between mitophagy and mitochondrial biogenesis in MELAS disease. Mitochondrial biogenesis may work as an AMPK-mediated compensatory mechanism in response to increased ROS production, reduced ATP levels and mitophagic degradation. Depending on the balance between both pathways, different degrees of pathological alterations can be detected among MELAS fibroblasts cell lines. Thus, mitochondrial proliferation may work as a compensatory mechanism triggered by the respiration defect [65] . As mitophagy and mitochondrial biogenesis are two processes that regulate mitochondrial content and preserve cell homeostasis [66] , the tight regulation between these pathways is crucial for cellular adaptation in response to cellular stress and other intracellular or environmental signals. Interestingly, dysregulation between mitochondrial biogenesis and mitophagy results in progressive development of numerous diseases [66, 67] .
We hypothesize that reduced phosphorylation of AMPK is responsible for impaired autophagic flux, poor compensatory response to mitophagy and increased oxidative stress which in turn impairs the bioenergetics state of MELAS fibroblasts leading to a most severe phenotype.
A major challenge in MELAS disease is the moderate effectiveness of pharmacological therapies; in this sense, AMPK activators such as AICAR and CoQ, would provide new therapeutic opportunities. Based on these findings, we suggest that a deeper understanding of the signaling cascade induced by AMPK activation and its tissue-specific regulation may provide new targets for the treatment of mitochondrial dysfunction related diseases and particularly in MELAS disease.
Mitophagy activation was also demonstrated in MELAS transmitochondrial cybrids harbouring the A3243G mutation indicating that as a consequence of the mutation in mtDNA and not the product of a concomitant nuclear gene defect. MELAS cybrids also showed low AMPK activation, reduced nuclear PGC-1α foci and severe pathophysiological alterations that were restored by both AICAR and CoQ treatments.
AMPK is a serine/threonine kinase well conserved through evolution, and orthologs of the AMPK subunits have been found in all eukaryotic species [68] . AMPK acts as an energy sensor of the cell and works as a key regulator of mitochondrial biogenesis [69] . Functionally, AMPK activates pathways such as glycolysis and amino acid oxidation for ATP production, while concurrently inhibits energy-dependent pathways such as biosynthesis of fatty acids and gluconeogenesis [70] . AMPK acts as a sensor of cellular energy levels and can be activated by a decrease of the ATP/ADP ratio. Furthermore, it has been demonstrated that AMPK could be also activated in response to elevated mitochondrial ROS [71] . It has also been shown that skin fibroblasts with MERRF syndrome, another mitochondrial disease caused by mutations in mitochondrial tRNAs, produced high level of mitochondrial ROS associated with AMPK activation [72] .
But, why AMPK is not properly activated in MELAS 1 and MELAS 2 fibroblasts that showed low ATP/ADP ratios and high ROS production? Currently, the mechanism to explain AMPK insensitivity is unknown. We can speculate that these more severe phenotypes are caused by decreased sensitivity of AMPK activation as it has been reported during aging [73] and mitochondrial-related diseases as Fibromyalgia [74] .The loss of sensitivity of AMPK activation to bioenergetics imbalance and cellular stress may aggravate oxidative stress and reduce autophagic clearance and, as a result, MELAS cells show a more severe phenotype.
In response to oxidative stress elicited by mtDNA mutation-induced mitochondrial dysfunction, AMPK activation (phosphorylation at Thr172) would trigger several adaptive responses for cell survival [75] . In response to oxidative stress, AMPK can directly phosphorylate PGC-1α and FOXO3a, which in turn augment mitochondrial biogenesis (e.g., up-regulation of mtTFA, NFR1, and NFR2) and the antioxidant defence system response (e.g., the up-regulation of Mn-SOD and catalase).
In addition to antioxidant defence, AMPK has other effects on mitochondrial parameters as mitochondrial fusion and fission that have emerged as important processes that govern mitochondrial function [76] [77] [78] . Thus, a gain of function AMPK mutation in skeletal muscle has been reported to increase the expression of mitochondrial fusion/ fission proteins, Mfn2, optic atrophy 1 (OPA1), and dynamin-related protein 1 (Drp1) [79] which implicates AMPK in the regulation of mitochondrial dynamics. Furthermore, AMPK functionally prevents high-glucose induced mitochondrial fission in endothelial cells [80] , highlighting that AMPK activity promotes mitochondrial quality control processes.
Furthermore, AMPK activation acts at multiple levels to stimulate autophagy and autophagic flux [81, 82] and consequently may reduce autophagolysosome accumulation in cellular contexts of increased mitophagy.
All together these responses suggest that activation of AMPK plays an essential role in the up-regulation of mitochondrial biogenesis, antioxidant enzymes and autophagic flux, as the adaptive and compensatory responses to mitochondrial dysfunction for the survival of affected cells.
Since AMPK is differentially activated in MELAS fibroblast, AMPK activation signaling pathway is worthy of further investigation in relation to the pathophysiology of MELAS disease. In addition, considering AMPK a potential therapeutic target, it is imperative to investigate whether AMPK activators such as AICAR or CoQ or others, as resveratrol, are beneficial to patients with mitochondrial diseases in general and MELAS disease in particular.
Detection of secondary CoQ deficiency in MELAS disease is particularly interesting because CoQ supplementation can be an effective therapy for the patients. Low CoQ levels can also function as a biochemical marker of poor AMPK-dependent compensatory response in MELAS fibroblasts. Benefits for CoQ supplementation include: increase in mitochondrial electron transport and ATP production, improvement of antioxidant protection, beneficial alteration in redox signalling, and mitochondrial permeability transition pore stabilization that may protect against autophagy and apoptosis [83] . Our study suggests that CoQ deficiency is the result of increased mitophagy without proper compensatory response by mitochondrial biogenesis as it is seen in MELAS 1 and MELAS 2 fibroblasts. Therefore, CoQ treatment could be effective by alleviating the deficiency itself and by increasing mitochondrial biogenesis, the enzymatic antioxidant system response and autophagy clearance through AMPK activation. It has been described that either inhibition of Ca 2+/ calmodulin-dependent protein kinase kinase (CaMKK) or knock-down CaMKK blocked CoQ-induced AMPK phosphorylation, suggesting the involvement of calcium in CoQ-mediated AMPK signalling [36] . CoQ also increased the expression of PGC-1α at both the mRNA and protein levels. Knock down of AMPK with siRNA or inhibition of AMPK using an AMPK inhibitor (compound C) blocked CoQinduced expression of PGC-1α, indicating that AMPK plays a critical role in PGC-1α induction by CoQ [36] . Recently, it has been proposed that CoQ may activate Sirt1 and PGC-1α by increasing cyclic adenosine monophosphate (cAMP) levels that, in turn, activate AMPK [84] .
Conclusion
According to our data, (i) the lack of proper AMPK activation induces a more severe phenotype in MELAS fibroblasts, (ii) AMPK activation by AICAR or CoQ restores most of the pathophysiological alterations. These findings suggest that AMPK plays a central role in MELAS pathophysiology and could become a new possible therapeutic target. Identification of AMPK as a regulating factor in MELAS pathophysiology is expected to have significant influence for future approaches in therapeutic and monitoring management of MELAS patients.
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